Evolving treatment paradigms for vascular risk reduction in type 2 diabetes

Kannel WB Lipids, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J1985;110: 1100-07.

Stamler J. , Vaccaro O. , Neaton JD , Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care1993;16:434-44.

Gu K. , Cowie CC , Harris MI Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care1998;21:1138-45.

Sprafka JM , Burke GL , Folsom AR et al. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey . Diabetes Care1991;14:537-43.

Gu K. , Cowie CC , Harris MI Diabetes and decline in heart disease mortality in US adults. JAMA1999;281:1291-7.

Diabetes atlas. Available from www.eatlas.idf.org/prevalence

Haffner SM , Lehto S. , Rönnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction . N Engl J Med1998;339:229-34.

Juutilainen A. , Pyorala K. , Lehto S. et al. Type 2 diabetes as a 'coronary heart disease equivalent'. An 18-year prospective population-based study in Finnish subjects. Diabetes Care2005;28:2901-07.

Hu FB , Stampfer MJ , Haffner SM et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care2002; 25:1129-34.

The IDF consensus worldwide definition of the metabolic syndrome . Available from http://www.idf.org

Lamarche B. , Tchernof A. , Moorjani S. et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation1997;95:69-75.

The FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial . Lancet2005; 366:1849-61.

Chapman MJ Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis2003;171:1-13.

Staels B. , Dallongeville J. , Auwerx J. et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism . Circulation1998;98:2088-93.

Forcheron F. , Cachefo A. , Thevenon S. et al. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes2002;51:3486-91.

Feher MD , Caslake M. , Foxton J. et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev1999;15:395-9.

Vakkilainen J. , Steiner G. , Ansquer JC et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Study (DAIS). Circulation2003;107: 1733-7.

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes; the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet2001; 357:905-10.

Staels B. , Koenig W. , Habib A. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature1998;393:790-3.

Koh KK , Han SW , Quon MJ et al. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia . Diabetes Care2005; 28:1419-24.

Rubins HB , Robins SJ , Collins D. et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med2002; 162:2597-604.

Pyörälä K. , Pedersen TR , Kjekshus J. et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care1997;20:614-20.

Haffner SM , Alexander CM , Cook TJ et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Intern Med1999; 159:2661-7.

Goldberg RB , Mellies MJ , Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation1998;98:2513-19.

Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361:2005-16.

Sever PS , Dahlöf B. , Poulter N. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet2003;361:1149-58.

Colhoun HM , Betteridge DJ , Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004; 364:685-96.

Wanner C. , Krane V. , Marz W. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med2005;353: 238-48.

Kendall DM , Bergenstal RM Comprehensive management of patients with type 2 diabetes: establishing priorities of care. Am J Manag Care2001;7:S327-43.

Baigent C. , Keech A. , Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366: 1267-78.

Ansquer JC , Foucher C. , Rattier S. et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis2005;45:485-93.

Meade T. , Zuhrie R. , Cook C. et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ2002;325:1139.

Cusick M. , Meleth AD , Agran E. et al. Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care2005;28:617-25.

Stratton IM , Kohner EM , Aldington SJ et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis . Diabetologia2001;44:156-63.

Chew EY , Klein ML , Ferris FL et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol1996;114:1079-84.

Mogensen CE , Poulsen PL Microalbuminuria, glycemic control, and blood pressure predicting outcome in diabetes type 1 and type 2. Kidney Int Suppl2004;66: S40-41.

Stratton IM , Adler AI , Neil AW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ2000;321:405-12.

Gaede P. , Vedel P. , Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med2003;348:383-93.

Burke GL Arterial wall thickness is associated with prevalent cardiovascular disease in middle aged adults: the Atherosclerosis Risk in Communities (ARIC) study . Stroke1995;26:386-91.

Feher MD , Hepburn AL , Hogarth MB et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford)2003; 42:321-5.